Page 1459 - Williams Hematology ( PDFDrive )

1434 Part X: Malignant Myeloid Diseases Chapter 88: Acute Myelogenous Leukemia 1435

1147. Kudoh S, Asou H, Kyo T, et al: Emergence of karyotypically unrelated clone in remis- 1178. Matsunaga T, Takemoto N, Sato T, et al: Interaction between leukemic-cell VLA-4 and
sion of de novo acute myeloblastic leukaemias. Br J Haematol 89:531, 1995. stromal fibronectin is a decisive factor for minimal residual disease of acute myeloge-
1148. Jinnai I, Nagai K, Yoshida S, et al: Incidence and characteristics of clonal hematopoie- nous leukemia. Nat Med 9:1158, 2003.
sis in remission of acute myeloid leukemia in relation to morphological dysplasia. 1179. Becker PS, Kopecky KJ, Wilks AN, et al: Very late antigen-4 (VLA-4) function of
Leukemia 9:1756, 1995. myeloblasts correlates with improved overall survival for patients with acute myeloid
1149. Robert EE: Spontaneous complete remission in acute promyelocytic leukemia. N Y leukemia. Blood 113:866, 2009.
State J Med 86:662, 1985. 1180. Estrov Z, Thall PF, Talpaz M, et al: Caspase 2 and caspase 3 protein levels as predictors
1150. Takue Y, Culbert SJ, Van Eys J, et al: Spontaneous cure of end-stage acute nonlymphocytic of survival in acute myelogenous leukemia. Blood 92:3090, 1998.
leukemia complicated with chloroma (granulocytic sarcoma). Cancer 58:1101, 1986. 1181. Frehling S, Schlenk RF, Stolze I, et al: CEBPA mutation in younger adults with acute
1151. Jehn UW, Mempel MA: Spontaneous remission of acute myeloid leukemia. Blut myeloid leukemia and normal cytogenetics: Prognostic relevance and analysis of
52:165, 1986. cooperating mutations. J Clin Oncol 22:624, 2004.
1152. Passe S, Miké V, Mertelsmann R, et al: Acute nonlymphoblastic leukemia: Prognostic 1182. Hollink IH, Zwaan CM, Zimmermann M, et al: Favorable prognostic impact of NPM1
factors in adults with long-term follow-up. Cancer 50:1462, 1982. gene mutations in childhood acute myeloid leukemia, with emphasis on cytogeneti-
1153. Evansen SA, Stavem P: Long-term survival in acute leukemia. Acta Med Scand 219:79, cally normal AML. Leukemia 23:262, 2009.
1986. 1183. Yanada M, Borthakur G, Garcia-Manero G, et al: Blood counts at time of complete
1154. Grunwald HW: The cure of acute myeloblastic leukemia in adults. JAMA 247:1698, remission provide additional independent prognostic information in acute myeloid
1982. leukemia. Leuk Res 32:1505, 2008.
1155. MacMahon B, Forman D: Variations in the duration of survival of patients with acute 1184. Hussein K, Jahagirdar B, Gupta P, et al: Day 14 bone marrow biopsy in predicting
leukemia. Blood 12:683, 1957. complete remission and survival in acute myeloid leukemia. Am J Hematol 83:446,
1156. Menzin J, Lang K, Earle C, et al: The outcomes and costs of acute myeloid leukemia 2008.
among the elderly. Arch Intern Med 162:1597, 2002. 1185. Schwind S, Maharry K, Radmacher MD, et al: Prognostic significance of expression of
1157. Derolf AR, Kristinsson SY, Andersson TM, et al: Improved patient survival for acute a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: A
myeloid leukemia: A population-based study of 9,729 patients diagnosed in Sweden Cancer and Leukemia Group B study. J Clin Oncol 28:5257, 2010.
1973–2005. Blood 113:3666, 2009. 1186. Deneberg S, Guardiola P, Lennartsson A, et al: Prognostic DNA methylation patterns
1158. Burnett AK: Transplantation in first remission of acute myeloid leukemia. N Engl J in cytogenetically normal acute myeloid leukemia are predefined by stem cell chroma-
Med 339:1698, 1998. tin marks. Blood 118:5573, 2011.
1159. Burnett AK, Goldstone AH, Stevens RM, et al: Randomised comparison of addition 1187. Paietta E: Classical multidrug resistance in acute myeloid leukaemia. Med Oncol
of autologous bone-marrow transplantation to intensive chemotherapy for acute 14:53, 1997.
myeloid leukaemia in first remission: Results of MRC AML 10 trial. U.K. Medical 1188. Ino T, Miyazaki H, Isogai M, et al: Expression of P-glycoprotein in de novo acute
Research Council Adult and Children’s Leukaemia Working Parties. Lancet 351:700, myelogenous leukemia at initial diagnosis: Results of molecular and functional assays
1998. and correlation with treatment outcome. Leukemia 8:1492, 1994.
1160. Clift RA, Buckner CD: Marrow transplantation for acute myeloid leukemia. Cancer 1189. Hart SM, Ganeshaguru K, Hoffbrand AV: Expression of the multidrug resistance-as-
Invest 16:53, 1998. sociated protein (MRP) in acute leukaemia. Leukemia 8:2163, 1994.
1161. Gale RP, Butturini A: Transplants for acute myelogenous leukemia. Cancer Invest 1190. Guerci A, Merlin JL, Missoum N, et al: Predictive value for treatment outcome in
16:66, 1998. acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein
1162. Middeke JM, Beelen D, Stadler M, et al: Outcome of high-risk acute myeloid leukemia expression simultaneously determined by flow cytometry. Blood 85:2147, 1995.
after allogeneic hematopoietic cell transplantation: Negative impact of abnl(17p) and 1191. Leith CP, Chen IM, Kopecky KJ, et al: Correlation of multidrug resistance (MDR1)
–5/5q–. Blood 120:2521, 2012. protein expression with functional dye/drug efflux in acute myeloid leukemia by mul-
1163. Middeke JM, Fang M, Cornelissen JJ, et al: Outcome of patients with abnl(1p) acute tiparameter flow cytometry: Identification of discordant MDR/efflux+ and MDR1+/
myeloid leukemia after allogeneic hematopoietic stem cell transplantation. Blood efflux– cases. Blood 86:2329, 1995.
123:2960, 2014. 1192. Kohler T, Eller J, Leiblein S, et al: Mechanisms responsible for therapy resistance of
1164. Chen Y, Kantarjian H, Wang H, et al: Acute promyelocytic leukemia: A popula- acute myelogenous leukemia (AML). Int J Clin Pharmacol Ther 36:97, 1998.
tion-based study on incidence and survival in the United States, 1975–2008. Cancer 1193. Filipits M, Stranzl T, Pohl G, et al: Drug resistance factors in acute myeloid leukemia:
118:5811, 2012. A comparative analysis. Leukemia 14:68, 2000.
1165. Redaelli A, Stephens JM, Brandt S, et al: Short- and long-term effects of acute myeloid 1194. Massaad-Massade L, Ribrag V, Marie JP, et al: Glutathione system, topoisomerase
leukemia on patient health-related quality of life. Cancer Treat Rev 30:103, 2004. II level and multidrug resistance phenotype in acute myelogenous leukemia before
1166. Hsu C, Wang JD, Hwang JS, et al: Survival-weighted health profile for long-term sur- treatment and at relapse. Anticancer Res 17:4647, 1997.
vivors of acute myelogenous leukemia. Qual Life Res 12:519, 2003. 1195. Drach D, Zhao S, Drach J, Andreeff M: Low incidence of MDR1 expression in acute
1167. Kern W, Haferlach T, Schoch C, et al: Early blast clearance by remission induction promyelocytic leukaemia. Br J Haematol 90:369, 1995.
therapy is a major independent prognostic factor for both achievement of complete 1196. Paschka P, Marcucci G, Ruppert AS, et al: Adverse prognostic significance of KIT
remission and long-term outcome in acute myeloid leukemia: Data from the German mutations in adult acute myeloid leukemia with inv(16) and t(8;21): A Cancer and
AML Cooperative Group (AMLCG) 1992 Trial. Blood 101:64, 2003. Leukemia Group B Study. J Clin Oncol 24:3904, 2006.
1168. Elliott MA, Litzow MR, Letendre LL, et al: Early peripheral blood blast clearance dur- 1197. Hoyle CF, DeBastos M, Wheatley K, et al: AML associated with previous cytotoxic
ing induction chemotherapy for acute myeloid leukemia predicts superior relapse- therapy, MDS or myeloproliferative disorders: Results from the MRC’s 9th AML trial.
free survival. Blood 110:4172, 2007. Br J Haematol 72:45, 1989.
1169. Cortes JE, Kantarjian H, O’Brien S, et al: Clinical and prognostic significance of 1198. DeWitte T, Muus P, DePauw B, Haanen C: Intensive antileukemic treatment of
trisomy 21 in adult patients with acute myelogenous leukemia and myelodysplastic patients younger than 65 years with myelodysplastic syndromes and secondary acute
syndromes. Leukemia 9:115, 1995. myelogenous leukemia. Cancer 66:831, 1990.
1170. Marcucci G, Maharry K, Radmacher MD, et al: Prognostic significance of, and gene 1199. Brito-Babapulle F, Catovsky D, Galton DAG: Clinical and laboratory features of de novo
and microRNA expression signatures associated with, CEBPA mutations in cytoge- acute myeloid leukaemia with trilineage myelodysplasia. Br J Haematol 66:445, 1987.
netically normal acute myeloid leukemia with high-risk molecular features: A Cancer 1200. Brito-Babapulle F, Catovsky D, Galton DAG: Myelodysplastic relapse of de novo acute
and Leukemia Group B Study. J Clin Oncol 26:5078, 2008. myeloid leukaemia with trilineage myelodysplasia. Br J Haematol 68:411, 1988.
1171. Buchner T, Heinecke A: The role of prognostic factors in acute myeloid leukemia. 1201. Rosenthal NS, Farhi DC: Dysmegakaryopoiesis resembling acute megakaryoblastic
Leukemia 10(Suppl 1):S28, 1996. leukemia in treated acute myeloid leukemia. Am J Clin Pathol 95:556, 1991.
1172. Ghaddar HM, Pierce S, Reed P, Estey EH: Prognostic value of residual normal meta- 1202. Layton DM, Ireland RM, Mufti GJ, Bellingham AJ: Myelodysplastic relapse of de novo
phases in acute myelogenous leukemia patients presenting with abnormal karyotype. AML: A heterogenous entity. Leuk Res 11:1055, 1987.
Leukemia 9:779, 1995. 1203. Jowitt SN, Yin JAL, Saunders MJ: Relapsed myelodysplastic clone differs from acute
1173. Seol JG, Kim ES, Park WH, et al: Telomerase activity in acute myelogenous leukaemia: onset clone as shown by X-linked DNA polymorphism patterns in a patient with acute
Clinical and biological implications. Br J Haematol 100:156, 1998. myeloid leukemia. Blood 82:613, 1993.
1174. Huh Y, Smith TL, Collins P, et al: Terminal deoxynucleotidyl transferase expression 1204. O’Brien S, Kantarjian HM, Keating M, et al: Association of granulocytosis with poor
in acute myelogenous leukemia and myelodysplasia as determined by flow cytometry. prognosis in patients with acute myelogenous leukemia and translocation of chromo-
Leuk Lymphoma 37:319, 2000. somes 8 and 21. J Clin Oncol 7:1081, 1989.
1175. Del Poeta G, Venditti A, Del Principe MI, et al: Amount of spontaneous apoptosis 1205. Krykowski E, Polkowska-Kulesza E, Robak T, et al: Analysis of prognostic factors in
detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML). acute leukemias in adults. Haematol Blood Transfus 30:369, 1987.
Blood 101:2125, 2003. 1206. Greenwood MJ, Seftel MD, Richardson C, et al: Leukocyte count as a predictor of
1176. Ong YL, McMullin MF, Bailie KE, et al: High bax expression is a good prognostic death during remission induction in acute myeloid leukemia. Leuk Lymphoma
indicator in acute myeloid leukaemia. Br J Haematol 111:182, 2000. 47:1245, 2006.
1177. Amirghofran Z, Zakerinia M, Shamseddin A: Significant association between expres- 1207. Bernard P, Reiffers J, LaComb F, et al: A stage classification for prognosis in adult
sion of the CD11b surface molecule and favorable outcome for patients with acute acute myelogenous leukaemia based upon patient’s age, bone marrow karyotype, and
myeloblastic leukemia. Int J Hematol 73:502, 2001. clinical features. Scand J Haematol 32:429, 1984.

Kaushansky_chapter 88_p1373-1436.indd 1434 9/21/15 11:02 AM